There's no vaccine for this
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Woman tragically died after choking on Nutella and toast
A review into the circumstances surrounding the death of a woman who choked on Nutella and toast has found that a number of things could have been done better in terms of her care. Tina, from Birkenhead, was 61 when she died in hospital on November 20 2017. She had been taken there by ambulance the day before, only a day and a half after moving to an emergency care placement in Knowsley. Tina had been found unresponsive by a member of staff, who had left her alone briefly to get the phone while she was eating. Despite being placed on life support, she later died and her death was recorded as hypoxic brain injury, cardiac arrest, and choking on food. Tina was described as 'a sociable funny person' who was close to her sisters, liked listening to music, and eating chocolate. She was diagnosed with cerebral palsy as an infant, had difficulty with her speech, and as an adult had no teeth or dentures. READ MORE: Tribute to mum with 'kindest soul' found dead at home READ MORE: Couple 'scammed' by £170 airport parking fine after falling asleep She had a number of health issues including mobility and breathing problems, incontinence, and was classed as morbidly clinically obese. A report into her death said she 'had choking risks associated with eating too fast, not chewing sufficiently, and having too much food in her mouth at once.' Tina's case is one of two adult safeguarding reviews included in an annual update for Wirral councillors at an adult social care and public health committee meeting on July 15. Tina was initially cared for by her family but was later put into care under Wirral Council. The report said she did not like to be identified by her disability and did not like it if her support staff would discuss her weight or attempt to control her eating of chocolate. The review said she would throw herself on the floor or attempt to swallow batteries, latex gloves, and plastic items and could on occasion be 'verbally abusive and sometimes aggressive.' In November 2017, Tina had to move as her permanent accommodation was being upgraded. An emergency placement at a care home broke down and she became unhappy, prompting her to be moved three times on November 17. Following her death, it was deemed the circumstances around her death and the number of agencies involved meant 'there was reason to pursue further enquiries about potential organisational neglect that might have contributed to her early death.' On November 19, Tina asked for a roast dinner, dessert, and chocolate buttons as well as toast and Nutella. Notes said Tina was given 'lightly toasted bread cut into small pieces.' After Tina was found choking and needing emergency CPR, she was later taken to Whiston Hospital where she died at 5.30am on November 20. Tina's assessment said she needed supervision when eating to avoid any choking risk. A number of issues with the support provided was highlighted in the review and seven recommendations were made as a result. However some good areas of practice around communication, engagement with Tina and her family over her care, as well as support for community activities and the services involved were thanked for their willingness to improve. For the latest news and breaking news visit Get all the big headlines, pictures, analysis, opinion and video on the stories that matter to you. Follow us on Twitter @LivECHONews - the official Liverpool ECHO Twitter account - real news in real time. We're also on Facebook/theliverpoolecho - your must-see news, features, videos and pictures throughout the day from the Liverpool ECHO.
Yahoo
37 minutes ago
- Yahoo
Topflight Pharma Development Veteran Joins Synendos
Dr. George Garibaldi is named Chief Medical Officer (CMO) as Synendos transitions from Phase 1 into Phase 2 of its clinical development strategy Dr. George Garibaldi, MD BASEL, Switzerland, July 15, 2025 (GLOBE NEWSWIRE) -- Synendos Therapeutics ('Synendos'), the clinical-stage biotechnology company developing breakthrough therapies for neuropsychiatric disorders, announced today that it has named Dr. George Garibaldi, CMO. This appointment is particularly timely as the company moves towards Phase 2 clinical development of its lead drug asset SYT-510. Synendos CEO, Andrea Chicca said, "It's tremendous that Synendos can attract this calibre of talent and experience. George offers a nuanced clinical perspective on the urgent needs of the patients we are looking to help, combined with specific expertise in advancing transformative neuroscience therapies from concept to clinical adoption.' Dr. George Garibaldi is a psychiatrist and neuroscientist with more than 30 years of experience leading global clinical development programs in CNS disorders. His career spans leadership roles at Roche, Novartis and Janssen, where he oversaw the development of breakthrough treatments including Ocrevus® for primary progressive and relapsing remitting multiple sclerosis and Exelon® for Alzheimer's disease and Lewi body dementia. As co-founder of Noema Pharma, he spearheaded the in-licensing and advancement of shelved CNS assets, securing major venture funding and progressing them through pivotal clinical trials. Known for his strong beliefs in empowering patients, Dr. Garibaldi has published more than 100 peer-reviewed articles and has developed widely used clinician- and patient-reported outcome measures. He is a founder and past president of the International Society for CNS Clinical Trials and Methodology and is recognized by peers as a collaborative, strategic leader dedicated to advancing mental health and neuroscience therapeutics. 'Mental health and brain health have for far too long been underserved by traditional drug development models,' said Dr. Garibaldi. "Synendos is combining the pursuit of an innovative target with a commitment to rethinking how we design trials, measure outcomes and prioritize patient function. It's this willingness to be ahead of the curve with therapeutic innovation and a genuine patient focus that made me want to be part of the company.' He added, 'Society today recognizes that there is no health without mental health. We have the rare opportunity to chart our own path here. I am eager to lead this transformation and help this exceptional team advance the next generation of brain therapies that could truly change the lives of patients.' About SynendosSynendos is a clinical-stage, neuroscience company developing potentially breakthrough therapies for neuropsychiatric and other CNS disorders such as anxiety disorders, PTSD and other indications. We utilise the modulation of a new drug target in the endocannabinoid system (ECS) that enables restoration of the natural functioning of the brain. Synendos' lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs). SERIs represent first-in-class, new chemical entities that modulate the ECS through a self-limiting mode of action (MoA) with the potential to deliver meaningful benefits to patients. This novel MoA has the potential to combine treatment of a range of symptoms with sustained efficacy in large patient populations together with the potential to address a key unmet need, that of chronic tolerability, allowing more patients to stay on treatment and regain an improved quality of life. For more information please contact: Synendos Therapeutics AG Simon Russell +41 79 138 5840 O Public Relations GmbHO'Patrick Wilson o@ 78 888 4332 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Man raises thousands for Parkinson's charity with 400-mile cycle
A man has raised more than £5,500 for a charity dedicated to finding a cure for Parkinson's disease. Rickmansworth resident Andrew Parkes cycled 400 miles over four days from Aberdaron in Wales to Margate, Kent, in support of Cure Parkinson's. Andrew Parkes (centre) has raised more than £5,500 for Cure Parkinson's. (Image: Sue Lacey) Andrew decided to take on the challenge as his mother lives with the progressive neurological condition. "I'm fundraising to help myself deal with the tragic way my mother has been affected," he said. "To hopefully find a cure so others may be spared. "It's a way to feel like I am paying it forward in a small way." Fundraising page: Andrew cycled 400 miles from Wales to Kent in over four days. (Image: Sue Lacey) He regularly cycles between five and 10 miles a day to visit his mum and is part of a mountain biking group, but the 400-mile cycle was still not without its challenges. Andrew said: "The most challenging aspect of the ride will probably be sitting in the saddle nine hours a day for four days, also trying to co-ordinate fundraising."It's not really very challenging in comparison to coping with Parkinson's though." Helen Matthews, CEO of Cure Parkinson's, said: "Fundraising support is absolutely critical for the charity to enable us to achieve our goal." You can donate via
